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REASONABLE PRICING - A NEW TWIST FOR
MARCH-IN RIGHTS UNDER THE BAYH-DOLE
ACT
John H. Raubitschekt
Norman J. Latkertt
INTRODUCTION
In 1980, the Bayh-Dole Act gave universities and small
businesses the right to own their inventions created with federal
funding.' Prior to this time, the existing statutes required certain
agencies to own inventions arising from federally funded research.
The rationale of Bayh-Dole was simply this: if the law affords
broad marketplace prerogatives to the developers of government
funded inventions, the inventions are far more likely to be developed
and so made available to the public. To achieve this goal, ownership
is left with the innovators, rather than assigned to the government
agency that financed the research. The innovators are then free to
leverage their rights to their advantage, as intended by the patent
system.
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Georgetown Law Center. Member of the Bars of the District of Columbia and Virginia. The
views expressed herein are those of the authors and not necessarily of the Department of
Commerce or the U.S. Government.
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Department of Commerce's Director of Federal Technology, drafted the 1984 amendments to
that Act, the implementing regulation in 37 C.F.R. pt. 401 and the Federal Technology Transfer
Act of 1986.
1. This is the popular name of the law, which takes its name from the principal sponsors
in the Senate: Birch Bayh and Robert Dole. The actual name is the "University and Small
Business Patent Procedures Act."
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Although there was spirited opposition to Bayh-Dole when it
was debated in Congress, a broad political consensus ultimately
developed around the notion that market forces would do a better job
of commercializing government-funded technology than federal
agencies could. 2
The Act has been enormously effective. As The Economist:
Science Technology Quarterly concluded, the Act is "[p]ossibly the
most inspired piece of legislation to be enacted in America over the
past half-century." 3 In operation, Bayh-Dole fostered a potent four-
way partnership between researchers, their institutions, government,
and industry. That partnership has created a powerful engine of
practical innovation, producing many scientific advances that have
extended human life, improved its quality and reduced suffering for
millions of people.
Universities, in particular, have been very successful in
commercializing their inventions. Bayh-Dole is generally credited for
contributing to the dramatic increase over the last 25 years in the
number of university inventions reported, patents granted, royalty-
bearing licenses negotiated, collaborative research agreements signed,
and start-up companies founded. As noted by The Economist, since
1980, American universities have witnessed a ten-fold increase in
their patents and created more than 2,200 companies to exploit their
technology, which in turn has produced 260,000 new jobs; they now
contribute $40 billion annually to the American economy.4
Notwithstanding its unquestioned success, the Act has recently
been criticized on the basis that the public should not be charged, or
should be charged less, for goods based on inventions for which, the
opponents maintain, the taxpayers have already paid.5 There have
2. S. 414, 96th Cong. (1980). The bill passed the Senate 91-4 and resulted in the Bayh-
Dole Act, Pub. L. 96-517, 96th Cong., 94 Stat. 3015 (1980). The agencies' passive licensing
approach resulted in less than 4% of government patents being licensed as of 1975 in
comparison with 33% of university owned licensed patents. S. Rep. No. 96-480, at 2 (1979).
3. The Economist Newspaper and the Economist Group, Innovation's Golden Goose,
THE ECONOMIST: SCIENCE TECHNOLOGY QUARTERLY (2002), available at
http://www.economist.com/science/tq/displayStory.cfm?storyid=1476653 (last visited May 31,
2005).
4. Id.
5. This criticism is remarkably similar to the views of some opponents of Bayh-Dole.
See The University and Small Business Patent Procedures Act: Hearing on S. 414 before the
Senate Comm. on the Judiciary, 96th Cong. 157 (1979) (statement of Admiral Hyman Rickover)
[hereinafter University Hearing]. Admiral Rickover states "[i]n my opinion, Government
contractors-including small businesses and universities-should not be given title to
inventions developed at Government expense .... These inventions are paid for by the public
and therefore should be available for any citizen to use or not as he sees fit."
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been an increasing number of articles expressing this view and further
suggesting that Bayh-Dole was not intended to give innovators an
unfettered right to set market prices for their inventions, which has
contributed to the rising cost of health care, especially for patented
drugs.
One such article by Peter S. Arno and Michael H. Davis asserts
that "march-in rights" were clearly intended to combat the price of
drugs invented by universities with federal funds and identified to be
excessive. 6 It is the purpose of this article to analyze this assertion
and its consequences.
I. HISTORY OF MARCH-IN RIGHTS
A. 1947 Attorney General Report
March-in rights have a long history and were discussed in the
1947 Attorney General's Report and Recommendations to the
President.7 They were included in the proposed government patent
policy which was being developed to accompany the expansion of
government research and development programs after World War II,
6. Peter Amo & Michael Davis, Why Don't We Enforce Existing Drug Price Controls?
The Unrecognized and Unenforced Reasonable Pricing Requirements Imposed upon Patents
Deriving in Whole or in Part from Federally Funded Research, 75 TULANE L. REV. 631 (2001).
Arno and Davis presented similar arguments in an op-ed article. See Peter Arno & Michael
Davis, Paying Twice For the Same Drugs, WASHINGTON POST, March 27, 2002, at A21. This
was rebutted by Birch Bayh and Robert Dole in another op-ed article. See Birch Bayh and
Robert Dole, Our Law Helps Patients Get New Drugs Sooner, WASHINGTON POST, April 11,
2002, at A28, stating:
Bayh-Dole did not intend that government set prices on resulting products. The
law makes no reference to a reasonable price that should be dictated by the
government .... The [Arno and Davis] article also mischaracterizes the rights
retained by the government under Bayh-Dole. The ability of the government to
revoke a license granted under the act is not contingent on the pricing of the
resulting product or tied to the profitability of a company that has
commercialized a product that results in part from government-funded research.
The law instructs the government to revoke such licenses only when the private
industry collaborator has not successfully commercialized the invention as a
product.
7. U.S. Dept of Justice, INVESTIGATION OF GOVERNMENT PATENT PRACTICES AND
POLICIES, REPORT AND RECOMMENDATIONS OF THE ATTORNEY GENERAL TO THE PRESIDENT
(1947) [hereinafter RECOMMENDATIONS]. There are three volumes. The report was initiated by
a letter dated February 5, 1943 from President Franklin Delano Roosevelt to Attorney General
Francis Biddle. President Roosevelt felt there was a need for a uniform Government policy on
the ownership of inventions made by Government employees and contractors.
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as recommended by the presidential science adviser, Vannevar Bush. 8
The Attorney General's Report recommended that, generally, the
Government should own inventions made by contractors, but that in
special circumstances the contractor may be permitted to own its
inventions, provided that "[t]he contractor (or his assignee) shall be
required to offer nonexclusive licenses at a reasonable royalty to all
applicants" if the contractor or assignee does not place the invention
in adequate commercial use within a designated period.9
B. 1963 and 1971 Presidential Memoranda and Statements
Thereafter, similar provisions attached to contractor ownership
of inventions were described in the Presidential Memoranda and
Statements of Government Patent Policy by Presidents Kennedy
(1963) and Nixon (1971).1 0 These were implemented in the Federal
Procurement Regulations and various agency procurement
regulations. I1
1. The Kennedy Memorandum
According to section 1(f) of the Kennedy Memorandum, the
government shall have the right to require the granting of a
nonexclusive royalty-free license to an applicant if the contractor or
grantee who has been permitted to own the invention, or its licensee
or assignee, (1) has not taken effective steps within three years after
the patent issues to bring the invention to the point of practical
8. Vannevar Bush, Science: The Endless Frontier, (U.S. GOv'T PRINTING OFFICE July
1945), available at http://www.nsf.gov/od/lpa/nsf50/vbush1945.htm (last visited May 31, 2005)
(report to the President on a program for postwar scientific research).
9. RECOMMENDATIONS, supra note 7, vol. 1 at 76, 110.
10. Memorandum of October 10, 1963, 28 Fed. Reg. 10,943 (Oct. 12, 1963) [hereinafter
Kennedy Memorandum]. Memorandum of August 23, 1971, 36 Fed. Reg. 16,887 (Aug. 26,
1971) [hereinafter Nixon Memorandum].
11. Federal Procurement Regulations § 1-9.107-3(b), 38 Fed. Reg. 23,782 (Sept. 4, 1973),
revised by 40 Fed. Reg. 19,814 (May 7, 1975) (codified at 37 C.F.R. § 401.14 and 48 C.F.R. §
52.227-11). Compare with Federal Nonnuclear Act of 1974 § 9(h), 42 U.S.C. § 5908(h)(6)
(2000) (repealed). A march-in like provision which allowed the head of the agency to terminate
a waiver of title or grant of an exclusive license if the recipient has not taken effective steps
necessary to accomplish substantial utilization of the invention. Section 9 was later repealed by
Bayh-Dole.) See discussion of march-in by the Department of Energy in GAO letter to Senator
Bayh dated July 17, 1979, reprinted in University Hearing, supra note 5, at 52-56. According to
DOE as reported by GAO, march-in was intended to address contractor windfall profits but has
not been utilized although available for more than 10 years because the problems are illusionary
and not actual. Id. at 56.
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application, 12 or (2) has made the invention available for licensing
royalty free or on terms that are reasonable in the circumstances, or
(3) can show why it should be able to retain ownership for a further
period of time. 13 As in the Attorney General's Report, the fourth
paragraph of the Kennedy Memorandum made clear that the reason
for march-in rights was to "guard against failure to practice the
invention." 14
2. The Nixon Memorandum
The march-in rights in section 1(f) of the Nixon Memorandum
are essentially the same as those in the Kennedy Memorandum, 15
except that the requirement was expanded to assignees and licensees
and the Government could also require the granting of an exclusive
license to a responsible applicant on terms that were reasonable under
the circumstances if the invention was not being developed.
Arno and Davis note that both Presidential Memoranda require
that licensing of inventions be on "reasonable terms." There is no
requirement in the Memoranda that the price of a patented invention
be on "reasonable terms."
C. Institutional Patent Agreements
Institutional Patent Agreements (IPAs) were first used by the
National Institutes of Health (NIH) beginning in 1968 and later by the
National Science Foundation (NSF) in 1973 to govern the
management of inventions made with NIH/NSF support by
universities with an approved patent policy. Since many of the
provisions in the Bayh-Dole Act come from IPAs, 16 Bayh-Dole can
12. "To the point of practical application" is defined as: "to manufacture in the case of a
composition or product, to practice in the case of a process, or to operate in the case of a
machine and under such conditions as to establish that the invention is being worked and that its
benefits are reasonably accessible to the public." Kennedy Memorandum, supra note 10, § 3(g).
13. Id. § (1)(f). Refers to principal or exclusive rights rather than ownership because of
the required irrevocable paid-up license for government purposes throughout the world.
14. Id.
15. Nixon Memorandum, supra note 10, § 1 (f). The definition of"to the point of practical
application" was unchanged. Id. § 4(g).
16. There are a number of common elements: (1) restriction against assignment of
inventions except to a patent management organization, (2) limitation on the term of an
exclusive license, which was removed when Bayh-Dole was amended in 1984, (3) requirement
that royalty income must be shared with inventors and the remainder used for education and
research purposes, (4) requirement that any patent application contain a reference to the federal
support which resulted in the invention and (5) requirement of granting a paid-up license to the
Government.
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be considered a codification of the IPA. Under both the NIH and
NSF IPAs, as in Bayh-Dole, the university had a contractual right to
elect ownership to any invention, thereby eliminating the arduous task
of justifying ownership after identification of an invention. Each IPA
contained all the conditions required by the Presidential Memoranda,
including march-in rights and the requirement to license on
"reasonable terms."
After receiving comments from many agencies and universities,
a model IPA containing these conditions was later developed for
government-wide use by the University Patent Policy Ad Hoc
Subcommittee of the Committee on Government Patent Policy of the
Federal Council of Science and Technology.17 Implementation of the
model IPA was postponed for 120 days at the request of Senator
Gaylord Nelson on March 17, 1978, who held hearings, 18 and sought
to receive recommendations by July 18, 1978.19
D. Use of March-In Prior to 1980
Before Bayh-Dole, there was little activity regarding march-in
rights.20 At most, the focus was on whether a particular invention
funded by the Government was being used. The absence of march-in
rights was discussed during the Nelson hearings. In particular,
Donald R. Dunner, the first Vice President of the American Patent
Law Association, indicated that:
17. The Subcommittee was chaired by Norman Latker and included John Raubitschek,
then patent counsel for NSF, as a member.
18. Government Patent Policies: Institutional Patent Agreements: Hearings before the
Subcommittee on Monopoly and Anticompetitive Activities of the Senate Select Committee on
Small Business, 95th Cong. 4 (1978), [hereinafter IPA Hearings].
19. Id. at 1004.
20. See Patent Policy: Hearings on S. 1215 Before the Senate Subcomm. on Science,
Technology and Space of the Comm. on Commerce, Science, and Transportation, 96th Cong.
366 (1979), where Dale Church of the Department of Defense responded to Senator Stevenson's
question, "Has the Department exercised march-in rights?", by remarking, "Only once can I
recall there was a case where we exercised march-in rights. It was a case involving two patents
held by MIT. There was a complainant who felt as though the patents were not being utilized.
As to one of the patents, it was found that MIT was using it and was allowed to retain exclusive
title. In the case of the other, we found that MIT was not effectively using it, and they did
provide for the complainant to use the patent." See also Lynn J. Alstadt, The 1980 Patent Rights
Statute: A Key to Alternate Energy Sources, 43 U. PITT. L. REv. 73, 95 n.121 (1981), which
discusses march-in activity at NIH, NSF and the Air Force, and Diane M. Sidebottom,
Intellectual Property in Federal Government Contracts: The Past, The Present and One
Possible Future, 33 PUB. CONT. L.J. 63, 95 n.245 (2003), which refers to two march-ins by the
predecessor to the Department of Energy in 1974. But these may have related to "waived"
inventions. See Federal Nonnuclear Act, supra note 11.
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Much has been said about march-in rights .... The point has been
raised that march-in rights have been available for 10 years, and
they have never been used; ergo, they are a failure. We submit that
is not the case. There is no evidence to indicate that march-in
rights should have been used in a specific situation and were not
used. In fact, we submit the high probability is quite the contrary.
Where an invention is significant, we submit that the marketplace
will take care of the situation. Competitors who want to use a
given piece of technology follow a standard routine procedure.
They first determine whether there is any patent cover on the
development, and then they evaluate the patent cover. If they feel
they want to get into the field, they will try to get a license. If they
cannot get a license in a Government-owned situation, they will go
to the Government agency involved, and they will say, 'I cannot
get a license.' They will point to the conditions which the IPA
specify as to when march-in rights should be applied; they will
provide the information necessary for that evaluation to be made,
and we submit in any given situation where march-in should be
applied, they will be applied.2 1
II. MARCH-IN RIGHTS UNDER BAYH-DOLE
Under Bayh-Dole, the Government's march-in rights are
described in 35 U.S.C. § 203. The funding agency may take action if
the contractor, grantee, or assignee has not taken, or is not expected to
take within a reasonable time, effective steps to achieve practical
application in a field of use. 22 This was clearly intended to follow the
precedent established in both Presidential Memoranda and the IPAs.
"Practical application" is defined in 35 U.S.C. § 201(f) to mean:
[T]o manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the
case of a machine or system; and, in each case, under such
conditions as to establish that the invention is being utilized and
21. IPA Hearings, supra note 18, at 577.
22. See generally 35 U.S.C. § 203 (2000). It is interesting that § 203 does not mention
"licensee" in addition to contractor, grantee, or assignee, as did the Nixon Memorandum and so
does not directly consider the commercialization activities of the contractor's licensee. There are
three other bases for exercising march-in rights. Id. § 203(l)(a). Two relate to health, safety or
public use and so are similar to the Nixon Memorandum except that they come into play only if
the contractor, grantee, assignee or licensee cannot reasonably alleviate or satisfy such needs.
The third basis relates to a breach of the "domestic manufacturing" requirement in 35 U.S.C. §
204 (2000). See 35 U.S.C. § 203(l)(b)-(d) (2000).
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that its benefits are to the extent permitted by law or Government
regulations available to the public on reasonable terms. 23
Section 203 not only authorizes the funding agency to require the
contractor or grantee, or its assignee or exclusive licensee, to grant a
license to a responsible applicant but itself can grant a license if the
ordered party refuses to do SO. 24
According to the legislative history of Bayh-Dole:
The Government may "march-in" if reasonable efforts are not
being made to achieve practical application, for alleviation of
health and safety needs, and in situations when use of the invention
is required by Federal regulations. "March-in" is intended as a
remedy to be invoked by the Government and a private cause of
action is not created in competitors or other outside parties,
although it is expected that in most cases complaints from third
parties will be the basis for the initiation of agency action. 25
Any decision to exercise march-in is subject to appeal to the
Court of Federal Claims within 60 days. The agency's decision is
held in abeyance until all appeals are exhausted. A decision not to
exercise rights is not reviewable. 26
The Bayh-Dole regulation in 37 C.F.R § 401.6 sets forth a
detailed multi-step process, although the agency can terminate the
proceedings at any time.27 The regulation allows an agency to initiate
a march-in proceeding "[w]henever [it] receives information that it
believes might warrant the exercise of march-in rights."'28 Since the
regulation provides no criteria for the initiation of a proceeding, an
agency appears to have unlimited discretion on whether or not to
23. This definition differs from those of the Kennedy and Nixon Memoranda, which say
merely "that its benefits are reasonably accessible to the public."
24. Licensing by the Government would be unusual since it is not the patent owner. If
there were royalties, it is assumed that they would belong to the patentee or exclusive licensee.
25. S. REP. No. 96-480, supra note 2 at 33-34.
26. Id. at 34.
27. 37 C.F.R § 401.6(h) (2004). Thus, one author has concluded that the procedures have
a built-in asymmetry which discourages march-in. See Avital Bar-Shalom and Robert Cook-
Deegan, Patents and Innovation in Cancer Therapeutics: Lessons from CellPro, 80 THE
MILBANK QUARTERLY 637, 667 (2002):
The procedures stipulated in Bayh-Dole also have a built-in asymmetry that
discourages march-ins. If an agency decides not to march in, the case is over. If it
does decide to march in, the party whose patent is subject to compulsory
licensing can contest the decision, which compels the agency to defend its action
against a party with a strong financial stake.
28. 37 CFR § 401.6(b) (2004).
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initiate one.29 However, before initiating a proceeding, the agency is
required to notify the contractor and request its comments. 30
Since 1980, the government has not exercised march-in rights.31
This might be an indication that march-in is simply ineffective. 32 The
ineffectiveness is demonstrated by the discovery made by the
Government Accountability Office (GAO), which pointed out that
agencies do not seek commercialization reports from contractors and
so do not know if inventions are being commercialized. 33
Nevertheless, there have been three petitions to the Department of
Health and Human Services (HHS) in recent years.
On March 3, 1997, CellPro, Inc. asked HHS to march-in against
Johns Hopkins University. The matter involved Johns Hopkins'
exclusive licensee Baxter Healthcare Corporation on four patents
covering an antibody useful for the treatment of cancer (U.S. Patent
Nos. 4,965,204, 4,714,680, 5,035,994 and 5,130,144).34 The petition
was referred to NIH, which funded the research resulting in the
inventions. Dr. Harold Varmus, the Director of NIH, concluded that
march-in proceedings were not warranted in a decision dated August
1, 1997.35 Dr. Varmus argued that march-in proceedings were not
necessary because Baxter Healthcare Corporation, an exclusive
29. Failure to enforce a statute is presumptively discretionary and therefore unreviewable
under the Administrative Procedure Act. Heckler v. Chaney, 470 U.S. 821, 837-38 (1985).
However, Arno & Davis, supra note 6, 689-90 n.366, suggested that an argument could be made
that the detailed requirements in 35 U.S.C. § 202 (2000) amount to the kind of guidelines that
would render the agencies' actions reviewable.
30. 37 CFR § 401.6(b) (2004).
31. Several authors have suggested that the Government will never exercise these rights.
See generally Bar-Shalom and Cook-Deegan, supra note 27 and Kevin W. McCabe,
Implications of the CellPro Determination on Inventions Made with Federal Assistance: Will
the Government Ever Exercise Its March-in Rights?, 27 PUB. CONTR. L.J. 645 (1998). See also
University Hearing, supra note 5, at 160 (Admiral Rickover, no supporter of the Bayh-Dole Act,
considered that march-in as a safeguard was "largely cosmetic" because in the rare case of an
agency exercising march-in, it would take years of litigation).
32. To the contrary, Mr. Dunner has suggested that the lack of any march-in by an agency
does not mean it is a failure because there is no evidence of when it should have been used and
that the marketplace would take care of the need for march-in with significant inventions. See
University Hearing, supra note 5, at 577.
33. TECHNOLOGY TRANSFER: REPORTING REQUIREMENTS FOR FEDERALLY SPONSORED
INVENTIONS NEED REVISION, GAO/RCED-99-242, at 15-16 (U.S. General Accounting Office
1999).
34. Peter Mikhail, Hopkins v. CellPro: An Illustration That Patenting and Exclusive
Licensing of Fundamental Science Is Not Always in the Public Interest, 13 HARVARD J.L. TECH.
375, 385 (2000).
35. Determination In the Case of Petition of CellPro, Inc. (National Institutes of Health
August 1, 1997), available at http://www.nih.gov/news/pr/aug97/nihb-0l.htm (last visited
September I, 2005) [hereinafter Cellpro Determination].
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licensee, had taken steps to make its product available to the public on
reasonable terms by obtaining European approval and filing for FDA
approval. Dr. Varmus also noted that it would be inappropriate for
NIH "to procure for CellPro more favorable commercial terms that it
can otherwise obtain from the Court or from the patent owners."'36
This matter was complicated by the pending patent infringement suit
by Johns Hopkins University against CellPro filed in 1994, and
included appeals to the Federal Circuit, which ultimately sustained the
validity and infringement of the Hopkins patents.37
On January 29, 2004, James Love and Sean Flynn filed two
march-in petitions to HHS on behalf of Essential Inventions, Inc.,
relying on the Arno-Davis "reasonable pricing" theory. 38  Both
petitions were referred to NIH, which had funded the research
resulting in the two patented inventions.
One petition related to ritonavir, a drug for the treatment of
AIDS sold under the trade name of Norvir® and invented by Abbott
Laboratories under a $3.5 million grant from the National Institute for
Allergy and Infectious Diseases (NIAID) (U.S. Patent No.
6,232,333). 39 There were other Abbott patents (U.S. Patent Nos.
5,541,206, 5,635,523, 5,648,497, 5,674,882, 5,846,987 and
5,886,036) relating to specific formulations or delivery techniques for
Norvir®, which may not have been invented under the NIAID grant.
The petition appears to have been a reaction to Abbott's
increasing the U.S. retail price of Norvir® by 400% in December
2003, when it shifted from being a primary treatment agent to one
used in small doses to boost the effects of other anti-AIDS medicines.
Norvir® has been a very successful drug, with total sales of more than
36. Id. For a description and analysis of the Cellpro case by two NIH attorneys, see
Barbara M. McGarey & Annette C. Levey, Patents, Products, and Public Health: An Analysis of
the CellPro March-In Petition, 14 BERKELEY TECH. L.J. 1095 (1999). See also Tamsen Valoir,
Government Funded Inventions: The Bayh-Dole Act and the Hopkins v. Cellpro March-in
Rights Controversy, 8 TEX. INTELL. PROP. L.J. 211, 219-33 (2000). There has been some
criticism of the CellPro decision. See Bar-Shalom & Cook-Deegan, supra note 27; McCabe,
supra note 31; and Mikhail, supra note 34.
37. Johns Hopkins Univ. v. CellPro, Inc., 152 F.3d 1342 (Fed. Cir. 1998).
38. See Essential Inventions, Inc. Legal Documents, available at
http://www.essentialinventions.org/legal (last visited September 1, 2005). Both petitions
requested that HHS issue non-exclusive licenses on the same non-discriminatory terms but
suggested that each patent owner receive a 5% royalty from the generic drug companies.
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$1 billion since it was introduced, although sales fell to $100 million
in 2003 from a high of $250 million in 1998.40
A public meeting was held at NIH on May 25, 2004, to discuss
the petition on the patents on Norvir® owned by Abbott Laboratories.
Norman Latker, James Love, and former Senator Birch Bayh, one of
the principal co-sponsors of Bayh-Dole, as well as a number of other
people from universities and the private sector, spoke on the issue.41
In a decision dated July 29, 2004 and released on August 4,
2004, Dr. Elias Zerhouni, the Director of NIH, determined that NIH
did "not have information that leads it to believe that the exercise of
march-in rights might be warranted. '42 NIH found that the record
established that Abbott had met the standard for achieving practical
application by its manufacture, practice and operation of Norvir®, by
the drug's availability and use by patients with HIV/AIDS since 1996,
along with Abbott's active marketing. With respect to drug pricing,
NIH felt "that the extraordinary remedy of march-in is not an
appropriate means of controlling prices ... [which should be] left for
Congress to address legislatively." Further, any anti-competitive
behavior by Abbott should be addressed by the FTC. Essential
Inventions responded on August 4, 2004 disagreeing with NIH's
decision: "The plain language of the Bayh-Dole Act says that
government-funded inventions should be made 'available to public on
reasonable terms. "',43
The other petition related to latanoprost, a drug for the treatment
of ocular hypertension and glaucoma sold under the trade name of
Xalatan®, invented by Columbia University under a grant from the
National Eye Institute, and exclusively licensed to Pharmacia
Corporation, now owned by Pfizer (U.S. Patent No. 4,599,353).44
40. Associated Press, U.S. Won't Override AIDS Drug Patents, U.S.A. TODAY, Aug. 4,
2004, available at http://www.usatoday.com/news/washington/2004-08-04-aids-drugx.htm
(last visited September 1, 2005).
41. Press Release, Essential Inventions, Inc., Essential Inventions Responds to NIH
Refusal to Authorize Generic Versions of Overpriced AIDS Drug (Aug. 4, 2004), available at
http://www.essentialinventions.org/drug/nih05252004 (last visited September 4, 2005)
[hereinafter Press Release].
42. In the Case of NORVIR® Manufactured by Abbott Laboratories, Inc. (National
Institutes of Health July 29, 2004) (determination) available at
http://OTT.od.nih.gov/Reports/March-In-Norvir.pdf (last visited September 1, 2005).
43. Essential Inventions Responds to NIH Refusal to Authorize Generic Versions of
Overpriced AIDS Drug (August 4, 2004), available at
http://www.essentialinventions.org/drug/august42004pressrelease.htm (last visited September 4,
2005).
44. It is of interest that Amo & Davis, supra note 6 at 689, mentioned this drug as one
where there should have been price controls. An extensive history of this drug is provided by
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Pfizer owns at least three other U.S. patents (5,296,504, 5,422,368
and 6,429,226) relating to Xalatan®, none of which were made with
federal funds and so are not subject to march-in. According to the
petition, Pfizer sells Xalatan® in the United States for two to five
times the price charged in Canada and Europe. The drug is said to
cost as much as $65 for a four to six week supply, although the cost of
the active ingredient is less than 1% of the sales price. By 2000, the
sales of Xalatan® were over $500 million a year. The petition
considered this unreasonable in view of over $4 million of taxpayer
support for the research at Columbia University.
In a decision by Dr. Zerhouni dated September 17, 2004, the
National Institutes of Health "determined that it will not initiate a
march-in proceeding as it does not believe such a proceeding is
warranted based on the available information and the statutory and
regulatory framework." 45  The basis for the decision was that the
record "demonstrates that Pfizer has met the standard for achieving
practical application of the applicable patents by its manufacture,
practice, and operation of latanoprost and the drug's availability and
use by the public." With respect to the lower prices being charged in
Canada and Europe, NIH "believes that the extraordinary remedy of
march-in is not an appropriate means for controlling prices." Rather,
NIH felt that the lower foreign prices should be "appropriately left for
Congress to address legislatively."
A. "Reasonable Terms" Relate to Licensing
A review of the statute makes it clear that the price charged by a
licensee for a patented product has no direct relevance to march-in
rights. As set forth in 35 U.S.C. § 203(1)(a), the agency may initiate
a proceeding if it determines that the contractor or assignee has not
taken, or is not expected to take within a reasonable time, effective
steps to achieve practical application of an invention made under the
contract.46 In most funding agreements, the contractor will be a
Jeff Gerth & Sheryl Gay Stolberg, Drug Makers Reap Profits on Tax-Backed Research, N.Y.
TIMES, April 23, 2000, at Al. According to this article, when the patent application was filed in
1982, no drug company in the United States was interested in a license because of its unusual
approach to treating glaucoma.
45. In the Case of Xalatan® Manufactured by Pfizer, Inc. (National Institutes of Health
Sept. 17, 2004) (determination), available at http://OTT.od.nih.gov/Reports/March-in-
xalatan.pdf (last visited August 31, 2005).
46. Under 35 U.S.C. § 202(c)(7) (2000), a university is not permitted to assign its
invention without the approval of the agency except to a patent management organization.
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university or nonprofit organization. Under the law, the university
need only take "effective steps," not achieve practical application.47
If a university is not directly engaged in the development of its
invention, an agency should inquire as to what steps the university is
planning on taking to commercialize the invention in a reasonable
time. Since this involves future action and an undefined time period,
it is not clear how an agency would evaluate this. 48 On the other
hand, if the university has licensed a company to make, use and sell
the invention, it may be considered as having taken effective steps
even if no sales of the invention have yet to occur, assuming that the
licensee is making some efforts to commercialize the invention.49
"Practical application," as defined, requires the benefits of the
invention be "available to the public on reasonable terms." With
respect to a university patent owner, reasonableness would apply only
to its licensing terms and to neither the price nor the availability of the
licensed product. 50 Further, in any license agreement, the price of the
licensed product is left to the discretion of the licensee. 51
Furthermore, if the license agreement were to specify a minimum
sales price, this might constitute a violation of the antitrust laws. The
typical license agreement includes a "due diligence" clause, so if the
licensee is not adequately achieving commercialization, the university
can terminate the license and seek other licensees.
With Norvirg, Abbott Laboratories, not a university, was the
contractor and so was directly responsible for commercialization of
that invention. Since there was no license, there was no issue of
"reasonable terms," and the dramatic price increase in Norvir® and
the substantial funding of the research by NIH were not relevant. 52
47. 35 U.S.C. § 203(1)(a) (2000).
48. Under both the Presidential Memoranda, the time period was three years from the
issue date of the patent. See Kennedy Memorandum, supra note 10, and Nixon Memorandum,
supra note 10. A mere statement that a patent is available for licensing may not be sufficient.
49. See Cellpro Determination, supra note 35.
50. But in the CellPro march-in case, NIH interestingly concluded that practical
application had been achieved because the licensee was manufacturing, practicing and operating
the licensed product. See McGarey & Levey, supra note 36, at 1101. Of course, in view of the
substantial sales of Xalatan®, the benefits of this invention would have been reasonably
available to the public under this approach.
51. The model IPA contained a requirement that royalties "be limited to what is
reasonable under the circumstances or within the industry involved." Thus, the focus of
reasonable terms was on the licensing by the -universities and not the price of the licensed
product.
52. Essential Inventions, Inc. filed a complaint with the Federal Trade Commission on
January 29, 2004, alleging that the 400% increase in price for Norvirg on December 2003
constituted anti-competitive pricing practices and thus violated antitrust laws. Letter from
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Rather, since Norvir® is available to the public from Abbott, either
directly or through other companies that can purchase it from Abbott,
there was no basis to conduct a march-in rights proceeding under 35
U.S.C. § 203(1)(a). 53 By manufacturing and selling Norvir®, Abbott
has taken effective steps to achieve practical application. According
to the petition, the sales of Norvir® through 2001 have totaled more
than $1 billion and may reach $2 billion over the next ten years.
B. There is No Reasonable Pricing Requirement
Arno and Davis maintain that "[t]he requirement for 'practical
application' seems clear to authorize the federal government to
review the prices of drugs developed with public funding under Bayh-
Dole terms and to mandate march-in when prices exceed a reasonable
level."'54 Arno and Davis further suggest that under Bayh-Dole, the
contractor may have the burden of showing that it charged a
reasonable price.55  This could be made part of its business
development or marketing plan.56
As we have mentioned previously, there is very little legislative
history on march-in rights and nothing relating to when they are to be
used. Similarly, Arno and Davis acknowledge that there is no clear
legislative history on the meaning of the phrase "available to the
public on reasonable terms,"57 yet they conclude that "[t]here was
Essential Inventions, Inc., to Susan Creighton, Director, Bureau of Competition - Federal Trade
Commission (January 29, 2004), available at
http://www.essentialinventions.org/legal/norvir/ftcletter.pdf (last visited September 1, 2005).
On May 19, 2004, Senators Charles Schumer, John McCain and Fritz Hollins asked the FTC to
initiate an investigation into Abbott's sudden price increase for NorvirV. See Letter from
Schumer et al., United States Senate, to Timothy J. Muris, Chairman, Federal Trade
Commission (May 19, 2004), available at
http://www.essentialinventions.org/legal/norvir/schmccholl2FTC051904.pdf (last visited
September 1, 2005). The FTC later advised Abbott that it had no plans to investigate this
complaint. See Associated Press, supra note 40. Dr. Jeffrey Leiden, president of Abbot,
commented at the NIH public meeting on May 25, 2004, that the NIH funding of the invention
was around $3.5 million. Jeffrey M. Leiden, Abbot Laboratories Comments at NIH Public
Meeting Regarding Norvir® and Bayh-Dole March-in Provisions (May 25, 2004), available at
http://www.essentialinventions/drug/nih05252004/leiden.pdf (last visited June 29, 2005).
53. But see 35 U.S.C. § 203(1)(b) (2000), the march-in for health and safety needs.
54. Amo & Davis, supra note 6, at 651.
55. Id. at 653.
56. There is no requirement in Bayh-Dole for contractors to have such a plan although
there is one for Federal laboratories in 35 U.S.C. § 209 (2000). In 2000, Congressman Sanders
offered an amendment to HHS appropriations bill H.R. 4577 that would apply the licensing
requirements for Federal laboratories to universities. See discussion of Sanders' amendment in
Arno & Davis, supra note 6, at 635 n.12, 666-67 n.227. The amendment was not adopted.
57. Amo & Davis, supra note 6, at 649.
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never any doubt that this meant the control of profits, prices, and
competitive conditions.1 58
Support for this surprising conclusion that "reasonable terms"
means "reasonable prices" is found in unrelated testimony during the
Bayh-Dole hearings, and in other Government patent policy bills that
did not become law, as well as in a number of non-patent regulatory
cases. 59 Even if "reasonable terms" is interpreted to include price that
does not necessarily mean that patented drugs funded by the
Government must be sold at reasonable prices.
If Congress meant to add a reasonable pricing requirement, it
would have explicitly set one forth in the law, or at least described it
in the accompanying reports. 60 That a new policy could arise out of
silence would truly be remarkable. There was no discussion of the
shift from the "practical application" language in the Presidential
Memoranda and benefits being reasonably available to the public, to
benefits being available on reasonable terms under 35 U.S.C. § 203.
On the other hand, there was much debate during the Bayh-Dole
hearings on whether there should be a recoupment provision to
address any windfall profits that a university may make out of
research funded by the Government. 61 There was a recoupment
provision in S. 414 as passed by the Senate but it did not become
law.62 Further, the pre-1984 limitation on the length of an exclusive
license term in Bayh-Dole meant that other companies would have
access to the patented technology after five years from the first
commercial sale or eight years from the date of license.63
After convincing themselves that they have made their case,
Arno and Davis criticize Bayh-Dole and the Department of
Commerce's implementing regulation in 37 C.F.R 401 for leaving the
enforcement of reasonable prices up to the agencies. 64 Finally, Arno
and Davis accuse the GAO of committing the "fatal error of
58. Id. at 662.
59. Compare this with Arno and Davis' opinion of NIH's "unbelievable" complaints that
price review is beyond its ability notwithstanding the "countless" cases and "host of' statutes to
the contrary. See Arno & Davis, supra note 6, at 651-52.
60. Admiral Rickover in his testimony on Bayh-Dole never suggested a reasonable pricing
requirement as a condition for allowing universities to retain title to their inventions made with
government funds. Rather, he proposed to give universities and small businesses an automatic
five-year exclusive license after which the invention would fall into the public domain, thereby
obviating the need for march-in and recoupment. University Hearing, supra note 5, at 161-62.
61. S. Rep. 96-480, supra note 2, at 25-26.
62. S. 414, supra note 2, § 204 (Return of Government Investment).
63. Pub. L. 98-620 (1984) deleted this exclusive licensing restriction.
64. Amo & Davis, supra note 6, at 648-49.
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confusing march-in rights with simple working requirements. '65 Of
course, all this criticism is misplaced, since there is no evidence that
Congress intended there to be a reasonable pricing requirement in
Bayh-Dole.
The authors submit that the interpretation taken by Arno and
Davis is inconsistent with the intent of Bayh-Dole, especially since
the Act was intended to promote the utilization of federally funded
inventions and to minimize the costs of administering the technology
transfer policies.66 As pointed out by Justice Brennan, a thing may be
within the letter of the law but not within the purpose of the law. 67
On the other hand, this would not be the case if agencies were
responsible for ensuring reasonable prices for any patented invention,
not just a drug, arising out of federal funding. Further, one of the
stated objectives of Bayh-Dole, found in 35 U.S.C. § 200, is to
"protect the public against nonuse or unreasonable use."'68 It neither
provides for, nor mentions, "unreasonable prices. '69
In H.R. 6933,70 a companion bill to S. 414 which resulted in
Bayh-Dole, there was a march-in rights provision-§ 387-which
was similar in part to 35 U.S.C. § 203(1)(a). Under § 387(a)(1) of the
provision, an agency could terminate the contractor's title or
exclusive rights, or require the contractor to grant licenses if the
contractor had not taken and was not expected to take timely and
effective action to achieve practical application in one or more fields
65. Id. at 676 n.273.
66. 35 U.S.C. § 200 (2000).
67. United Steelworkers of America v. Weber, 443 U.S. 193, 201 (1979), citing Holy
Trinity Church v. U.S., 143 U.S. 457, 459 (1892) and discussed in Judge Ruggero J. Aldisert,
The Brennan Legacy: The Art of Judging, 32 LOY. L.A. L. REv. 673, 682-83 (1999).
68. Thus, an agency may march-in for reasons other than non-use of an invention. See S.
REP. 96-480, supra note 2 at 30 ("The agencies will have the power to exercise march-in rights
to insure that no adverse effects result from retention of patent rights by these contractors."). As
Dr. Betsy Ancker-Johnson, former Assistant Secretary of Commerce, explained, the purpose for
march-in rights is to correct "should something go wrong" and if there is "any remote possibility
of abuse." See University Hearing, supra note 5 at 153-54. Unfortunately, no guidance was
given on how to determine what is an abuse and this may refer to the other march-ins in 35
U.S.C. § 203(a)(2)-(4) (2000). On the other hand, there may be a situation where a contractor is
using an invention for itself but not making the benefits of the invention available to the public
at all or on reasonable terms, which could include price. This might be a basis for march-in as
mentioned by David Halperin, The Bayh-Dole Act and March-in Rights, at 6 (May 2001)
available at http://www.essentialinventions.org/legal/norvir/halperinnarchin200l.pdf (last
visited September 1, 2005), although we disagree with the "reasonable pricing" arguments he
adopted from Arno and Davis.
69. Arno & Davis, supra note 6 at 683, argued that "unreasonable use" includes
unreasonable prices.
70. H.R. 6933, 96th Cong. (1980).
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of use. According to the legislative history, 71 this section was
"intended to continue existing practice and the [House Judiciary]
Committee intends that agencies continue to use the march-in
provisions in a restrained and judicious manner as in the past. '72
Although H.R. 6933 ultimately incorporated S. 414, the
discussion by the House Judiciary Committee is considered relevant
to 35 U.S.C. § 203 because of the similarity in language and the fact
that it is included in the legislative history of Bayh-Dole. Thus, it
does not appear that Congress intended that there be any change in the
application of march-in rights by the agencies, which prior to that
time focused on the non-utilization or non-working of federally
funded patented inventions, as is evident from the previous discussion
of the history under the Presidential Memoranda and the IPAs.73
The authors recognize that 35 U.S.C. § 203 includes the
language "available on reasonable terms," but one has to understand
the context of the phrase in the statute. As previously mentioned with
respect to the history of march-in and the two recent petitions to HHS,
that term relates only to licensing. Thus, a university licensing its
invention to a drug company that sells the patented product to the
public is fulfilling its responsibility under Bayh-Dole of making the
benefits of the invention available to the public on reasonable terms.
Although we disagree with the interpretation of 35 U.S.C. § 203
by Arno and Davis, Congress could decide to amend Bayh-Dole to
impose a reasonable pricing requirement. However, we would not
recommend such a change because of the difficulty in determining
what is "reasonable." 74  Furthermore, that would make any patent
license granted by a Government contractor or grantee subject to
attack,75 which would discourage or inhibit the commercialization of
71. H.R. REP. No. 96-1307, pt.1 (1980) reprinted in 1980 U.S.C.C.A.N. 6460, 6474.
72. Id. at 6474.
73. See Koons Buick Pontiac GMC, Inc. v. Nigh, 125 S. Ct. 460, 468 (2004), citing
Church of Scientology of Cal. v. IRS, 484 U.S. 9, 17-18 (1987), where the Supreme Court
focused on the lack of Congressional intent to significantly change the meaning of a clause by
referring to a Sherlock Holmes story. ("All in all, we think this is a case where common sense
suggests, by analogy to Arthur Conan Doyle's 'dog that didn't bark ....'). It is remarkable
that there is no discussion in the legislative history of Bayh-Dole about a reasonable pricing
requirement.
74. See testimony of Dr. Bernadine Healy, Director of NIH, on Feb. 24, 1993 that NIH is
not equipped, either by its expertise or its legislative mandate, to analyze private sector product
pricing decisions. Amo & Davis, supra note 6, at 670 n.245. Such a determination would be
further complicated by when it is done because of the long time and large funds it takes to get to
get a drug to market.
75. Although 35 U.S.C. § 203 (2000) applies only to nonprofit organizations and small
business firms, it was expanded to large businesses by 35 U.S.C. § 210(c) (2000).
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Government-funded technology, one of the primary purposes of the
Act.
7 6
It is of interest that NIH had a reasonable pricing policy several
years ago. In October 1991, NIH put a reasonable pricing clause in
an exclusive patent license with Bristol-Myers-Squibb for the use of
ddl, a new AIDS drug. 77 Around this time, NIH also had a reasonable
pricing clause in all of its cooperative research and development
agreements (CRADAs). 78 Dr. Harold Varmus, the Director of NIH,
withdrew the reasonable pricing requirement in its CRADAs in 1995
after convening panels of scientists and administrators in government,
industry, universities, and patient advocacy groups to review this
policy. 79 In a recent report to Congress, NIH acknowledges that
"[t]he cost of prescription drugs is a legitimate public concern that
exists whether or not a drug was developed from a technology arising
from federally funded research ... [but NIH] has neither the mandate
nor the authority to be the arbiter of drug affordability." 80
76. This could be especially damaging for biotech inventions. See McCabe, supra note
31, at 648. However, a contrary view is taken by Mary Eberle, March-In Rights Under the
Bayh-Dole Act: Public Access to Federally Funded Research, 3 MARQ. INTELL. PROP. L. REV.
155, 171 (1999) ("1 argue, by contrast, that a march-in under one of the four circumstances
enumerated in the Act would not harm technology transfer.").
77. The National Institutes of Health and its Role in Creating U.S. High-Technology
Industry Growth and Jobs: Hearing before the Subcomm. on Regulation, Business
Opportunities, and Energy of the House Comm. on Small Business, 102d Cong. 9 (1991). When
then Congressman Wyden asked about objections to this policy at NIH, Dr. Healy explained that
"we are not interested in price setting, but we are interested in using our leverage." Id. at 22.
She repeated later that NIH should not be involved in price setting. TPCC Report: Hearing
before Subcomm. on Regulation, Business Opportunities, and Technology of House Comm. on
Small Business, 103rd Cong. 16 (1993).
78. Arno and Davis suggest that march-in rights apply to CRADAs although they are not
funding agreements as defined by Bayh-Dole. See Amo & Davis, supra note 6, at 644-45.
However, CRADAs have their own march-in rights provision in 15 U.S.C. § 3710a(b)(l)(B) and
(C) (2000), although it is more limited than 35 U.S.C. § 203 (2000) and does not refer to
"practical application." The only mention of reasonable terms is with respect to a license to be
granted by the Government in § 3710a(b)(l)(B)(i). Similarly, there is a march-in like right in
the licensing of a Government-owned invention provided in 35 U.S.C. § 209(f)(2) and (4)
(2000) under which the Government may terminate the license.
79. National Institutes of Health, NIH Response to the Conference Report Request for a
Plan to Ensure Taxpayers' Interests are Protected (July 2001), available at
http://www.nih.gov/news/070101 wyden.htm (last visited September 1, 2005).
80. National Institutes of Health, Affordability of Inventions and Products, at 4 (July
2004), available at http://ott.od.nih.gov/New Pages/211856ottrept.pdf, (last visited June 4,
2005).
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CONCLUSION
There is no reasonable pricing requirement under 35 U.S.C. §
203(l)(a)(1), considering the language of this section, the legislative
history, and the prior history and practice of march-in rights. Rather,
this provision is to assure that the contractor utilizes or
commercializes the funded invention. 81
However, that does not mean that the price charged for a drug
invented with Government funding is never of concern to the funding
agency. There are other mechanisms to address this concern,
including the health march-in authority of 35 U.S.C. § 203(1)(a)(2),
the Government license in 35 U.S.C. § 202(c)(4), and eminent domain
in 28 U.S.C. § 1498(a). 82 In addition, NIH asserted co-inventorship
in AZT, which contributed to reducing the cost for this important
AIDS drug, sold by Burroughs Wellcome, even though the claim of
co-ownership was not sustained in court.8 3 Finally, discriminatory
pricing of drugs, whether or not invented with Government funds,
may fall within the responsibility of the Federal Trade Commission if
it can be found to be anti-competitive behavior in violation of
antitrust laws. 84
81. See Alstadt, supra note 20, at 81.
82. See McGarey & Levey, supra note 36, at 1113-15.
83. See Lacy et al., Technology Transfer Laws Governing Federally Funded Research and
Development, 19 PEPP. L. REv. 1, 2 (1991), and Ackiron, The Human Genome Initiative and the
Impact of Genetic Testing and Screening Technologies: Note and Comment: Patents for Critical
Pharmaceuticals: The AZT Case, 17 AM. J.L. & MED. 145 (1991). Dr. Healy explained that the
licensing of AZT by NIH was to lower Burroughs Wellcome's price, which went from $8,000-
10,000 to $2,000. The National Institutes of Health and its Role in Creating U.S. High-
Technology Industry Growth and Jobs: Hearing before the Subcommittee on Regulation,
Business Opportunities, and Energy of the House Committee on Small Business, 102d Cong. 23
(1991).
84. See NIH decision on the NorvirV march-in petition. National Institutes of Health,
supra note 42.
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